Healthcare Industry News: focused ultrasound
News Release - October 29, 2007
Medical Device Industry Veteran Michael Ryan Joins Misonix to Lead Medical Device Sales and Marketing Team
FARMINGDALE, N.Y.--(HSMN NewsFeed)--Misonix, Inc. (Nasdaq: MSON ) (“Misonix” or “the Company”), a developer of ultrasonic medical device technology for the treatment of cancer and other health conditions, announced today the appointment of Michael C. Ryan as Senior Vice President, Medical Division. Located at Misonix’s global headquarters in Farmingdale, New York, Mr. Ryan joined Misonix today and reports to Michael A. McManus, Jr., the Company’s President and Chief Executive Officer.Mr. Ryan’s career in the healthcare industry spans over 20 years, with senior level positions held at major medical device companies in sales management, market development, and business planning. Most recently he served as Senior Vice President and General Manager of NOMOS Radiation Oncology. Previously he worked in the areas of cardiology and interventional medical technologies, with tenures at Johnson & Johnson and Medtronic.
Commenting on the addition of Mr. Ryan, Mr. McManus said, “We are extremely pleased to have Michael Ryan working on our therapeutic medical products, including all of our products using High Intensity focused ultrasound, which represent substantial growth opportunities for our Company. Michael brings to Misonix substantial experience in management and sales of medical devices for some of the major companies in our industry. As an ideal addition to our team, his career has focused on the development, management, international distribution and world-class marketing and sales programs for global medical device companies. We look forward to working with him as we embark on our next phase of multi-year growth.”
About Misonix:
Misonix, Inc. (NASDAQ: MSON ) designs, develops, manufactures, and markets, therapeutic ultrasonic medical devices, and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissue without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking statements.
Source: Misonix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
